Literature DB >> 11883638

HPLC determination of binding of cisplatin to DNA in the presence of biological thiols: implications of dominant platinum-thiol binding to its anticancer action.

Erika Volckova1, Lea P Dudones, Rathindra N Bose.   

Abstract

PURPOSE: The purpose of this work is to evaluate the extent of the binding of cisplatin (cis-diamminedichloroplatinum(II)) to DNA in the presence and absence of biological thiols, glutathione, and cysteine, and to test the hypothesis whether the platinum-thiol complexes can serve as a drug reservoir for subsequent binding to DNA.
METHODS: Reactions of cisplatin (50 microM to 1.0 mM) with calf thymus DNA (870 microM to 6.75 mM) in the presence and absence of glutathione and cysteine (0 to 10 mM) were carried out at pH 4.4, 7.0, and 7.3. Following the reactions, the DNA was enzymatically digested with nucleases, separated by RP HPLC, and analyzed to determine the extent of DNA binding. The method was independently verified by proton NMR measurements.
RESULTS: At neutral pH, and equimolar concentrations of DNA and thiols, only a very small amount of platinum (<5%) was coordinated to DNA, and most of the platinum was coordinated to the thiols. At pH 4.4, binding to DNA was dominant over the binding to thiols. No conversion of platinum-thiol to platinum-DNA complexes was observed up to 7 days of incubation.
CONCLUSION: At physiological pH, the cisplatin was exclusively coordinated to biological thiols and platinum-DNA was a minor adduct. Data presented in this paper does not support the "drug reservoir" hypothesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883638     DOI: 10.1023/a:1014268729658

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

1.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

Authors:  E R Jamieson; S J Lippard
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

Review 2.  Activation of programmed cell death by anticancer agents: cisplatin as a model system.

Authors:  A Eastman
Journal:  Cancer Cells       Date:  1990 Aug-Sep

3.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

Authors:  M A Barry; C A Behnke; A Eastman
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

4.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer.

Authors:  M Morris; P J Eifel; J Lu; P W Grigsby; C Levenback; R E Stevens; M Rotman; D M Gershenson; D G Mutch
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

5.  Platinum(II)-adenosine phosphothiorate complexes: kinetics of formation and phosphorus-31 NMR characterization studies.

Authors:  L L Slavin; E H Cox; R N Bose
Journal:  Bioconjug Chem       Date:  1994 Jul-Aug       Impact factor: 4.774

6.  Cisplatin inhibits protein synthesis in rabbit reticulocyte lysate by causing an arrest in elongation.

Authors:  K A Heminger; S D Hartson; J Rogers; R L Matts
Journal:  Arch Biochem Biophys       Date:  1997-08-01       Impact factor: 4.013

7.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

Authors:  H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

Review 8.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.

Authors:  V M Richon; N Schulte; A Eastman
Journal:  Cancer Res       Date:  1987-04-15       Impact factor: 12.701

10.  The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

Authors:  P Mistry; L R Kelland; G Abel; S Sidhar; K R Harrap
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more
  8 in total

1.  Preferential energy- and potential-dependent accumulation of cisplatin-gutathione complexes in human cancer cell lines (GLC4 and K562): A likely role of mitochondria.

Authors:  Simplice Dzamitika; Milena Salerno; Elene Pereira-Maia; Laurence Le Moyec; Arlette Garnier-Suillerot
Journal:  J Bioenerg Biomembr       Date:  2006-05-27       Impact factor: 2.945

2.  The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin.

Authors:  Jiajiu Shaw; Joseph Media; Ben Chen; Fredrick Valeriote
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-24       Impact factor: 3.333

3.  Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues.

Authors:  Irina Buß; Ganna V Kalayda; Andreas Lindauer; Michael R Reithofer; Markus Galanski; Bernhard K Keppler; Ulrich Jaehde
Journal:  J Biol Inorg Chem       Date:  2012-03-29       Impact factor: 3.358

4.  Apoptosis of human breast carcinoma cells in the presence of cis-platin and L-/D-PPMP: IV. Modulation of replication complexes and glycolipid: Glycosyltransferases.

Authors:  Patrick J Boyle; Rui Ma; Narendra Tuteja; Sipra Banerjee; Subhash Basu
Journal:  Glycoconj J       Date:  2006-05       Impact factor: 2.916

5.  Kinetics and mechanism of the substitution reactions of [PtCl(bpma)]+, [PtCl(gly-met-S,N,N)] and their aqua analogues with L-methionine, glutathione and 5'-GMP.

Authors:  Zivadin D Bugarcić; Jovana Rosić; Biljana Petrović; Nadine Summa; Raph Puchta; Rudi van Eldik
Journal:  J Biol Inorg Chem       Date:  2007-08-21       Impact factor: 3.358

6.  Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells.

Authors:  Rathindra N Bose; Leila Maurmann; Robert J Mishur; Linda Yasui; Shefalika Gupta; W Scott Grayburn; Heike Hofstetter; Tara Salley; Tara Milton
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-19       Impact factor: 11.205

Review 7.  Metallodrugs are unique: opportunities and challenges of discovery and development.

Authors:  Elizabeth J Anthony; Elizabeth M Bolitho; Hannah E Bridgewater; Oliver W L Carter; Jane M Donnelly; Cinzia Imberti; Edward C Lant; Frederik Lermyte; Russell J Needham; Marta Palau; Peter J Sadler; Huayun Shi; Fang-Xin Wang; Wen-Ying Zhang; Zijin Zhang
Journal:  Chem Sci       Date:  2020-11-12       Impact factor: 9.825

8.  Sensitive Marker of the Cisplatin-DNA Interaction: X-Ray Photoelectron Spectroscopy of CL.

Authors:  Fangxing Xiao; Xiaobin Yao; Qianhong Bao; Danzhen Li; Yi Zheng
Journal:  Bioinorg Chem Appl       Date:  2012-10-24       Impact factor: 7.778

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.